Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

The aim of this randomized phase-II study was to evaluate the effect of substituting cytarabine by azacitidine in intensive induction therapy of patients with acute myeloid leukemia (AML). Patients were randomized to four induction schedules for two cycles: STANDARD (idarubicin, cytarabine, etoposid...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlenk, R. F., Weber, D., Herr, W., Wulf, G., Salih, H. R., Derigs, H. G., Kuendgen, A., Ringhoffer, M., Hertenstein, B., Martens, U. M., Grießhammer, M., Bernhard, H., Krauter, J., Girschikofsky, M., Wolf, D., Lange, E., Westermann, J., Koller, E., Kremers, S., Wattad, M., Heuser, M., Thol, F., Göhring, G., Haase, D., Teleanu, V., Gaidzik, V., Benner, A., Döhner, K., Ganser, A., Paschka, P., Döhner, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756041/
https://www.ncbi.nlm.nih.gov/pubmed/30728457
http://dx.doi.org/10.1038/s41375-019-0395-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756041/
https://www.ncbi.nlm.nih.gov/pubmed/30728457
http://dx.doi.org/10.1038/s41375-019-0395-y

Ejemplares similares